Aroxat

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aroxat

Property Description
Active ingredient Paroxetine hydrochloride
Form Oral tablet
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI), Antidepressant
Common use Modulation and stabilization of mood
Origin Synthetic compound

Aroxat is a prescription-only medication classified as a Selective Serotonin Reuptake Inhibitor (SSRI), a type of antidepressant used to help stabilize the brain's chemical balance. The drug is a synthetic compound that functions as a psychotropic medication, influencing complex central nervous system processes. This compound is recognized for its focused influence on mood regulation.

What Type of Medicine is Aroxat and What is its Classification?

Aroxat belongs to the antidepressant pharmacological class, specifically categorized as a Selective Serotonin Reuptake Inhibitor (SSRI). Its active ingredient, Paroxetine hydrochloride, is the same formulation found in several other preparations, including popular brands like Paxil and Seroxat, positioning Aroxat within a group of well-established therapeutic agents. This specific classification indicates that the drug's action is defined by its focused influence on the serotonergic agent system. This medication functions by regulating levels of a key neurotransmitter in the brain, which is essential for emotional balance.

Aroxat Composition and General Therapeutic Purpose

The active ingredient in Aroxat is Paroxetine hydrochloride, which constitutes the single-ingredient product administered via the oral route of administration as a tablet. The formulation is composed of the active Paroxetine compound alongside various solid pharmaceutical excipients necessary for stability and systemic delivery after ingestion. As a therapeutic agent, Aroxat’s general purpose is to assist in the central nervous system's capacity to regulate emotional states. The class to which Paroxetine belongs is recognized for its ability to affect mood and behavior regulation. For a patient, this means the medication is used in situations requiring support for emotional equilibrium, helping to modulate and stabilize mood by addressing the disruption of chemical balance associated with conditions requiring serotonergic intervention.

Regulatory References

  1. NIH

What side effects are possible with Aroxat?

Possible Side Effects and Safety Information: Aroxat (Paroxetine)

Official regulatory documents classify the safety profile of Aroxat based on the frequency and the affected body system of reported adverse reactions. This classification is guided by clinical data and post-marketing surveillance, providing a structured overview of potential effects.

Frequency-Classified Adverse Reactions

Adverse effects are formally categorized based on their documented rate of occurrence:

  • Very Common (Affecting 1 in 10): Nausea, sexual dysfunction (e.g., ejaculatory disturbance, anorgasmia).
  • Common (Affecting 1 in 100 to < 1 in 10): Somnolence, insomnia, dizziness, dry mouth, constipation, increased sweating, asthenia (weakness).
  • Uncommon/Rare: Less frequent effects involve systems such as the vascular system (e.g., bleeding disorders), the nervous system (e.g., confusion, tremor), and the metabolism (e.g., hyponatraemia).

Serious Adverse Reactions and Population-Specific Notes

The regulatory profile highlights serious adverse reactions, including the risk of Serotonin Syndrome, a potentially serious condition. Official labeling also documents an increased risk of suicidal thinking and behavior particularly in adolescents and young adults (under 25), especially at the start of treatment or following dose changes. Safety notes specify that older adults face a documented increased risk of hyponatraemia (low sodium levels) and bleeding events. Furthermore, regulatory guidelines advise caution in patients with hepatic impairment due to the potential for drug accumulation. The label also notes that abrupt discontinuation can lead to documented withdrawal-type symptoms (e.g., dizziness, sensory disturbances).

Overdose and Emergency Response

A suspected overdose of Aroxat (Paroxetine) requires immediate medical attention due to the potential for severe, life-threatening outcomes. Officially documented clinical manifestations of overdose include central nervous system effects such as somnolence, dizziness, tremor, and confusion, alongside gastrointestinal issues like nausea and vomiting. Cardiovascular changes, including tachycardia or bradycardia, and fluctuations in blood pressure (hypertension or hypotension), are also commonly reported signs listed in regulatory labeling.

Life-Threatening Risks and Emergency Actions

Aroxat overdose carries the documented risk of severe complications, including the development of potentially life-threatening Serotonin Syndrome, generalized convulsions (seizures), and significant ventricular arrhythmias such as Torsade de Pointes. Immediate emergency treatment must be sought if any overdose is suspected.

Because no specific antidote for paroxetine is known, regulatory documents mandate that management is centered on general supportive and symptomatic measures. These include maintaining an adequate airway and circulation, continuous monitoring of cardiac rhythm and vital signs, and administration of activated charcoal. Individuals with existing renal or hepatic impairment may experience increased plasma concentrations of the drug, which is a key consideration in overdose management.

Therapeutic Uses of Aroxat

Aroxat (Paroxetine) may be part of symptomatic management across therapeutic domains involving distressing symptoms in adults. It is commonly used to help ease the overall symptom load and supports general well-being during symptomatic phases. As a well-established SSRI, it has recognized clinical utility for these conditions.

The medication is applicable across conditions characterized by episodic or fluctuating manifestations, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder (PD), Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), and Posttraumatic Stress Disorder (PTSD). A specific formulation is also used for severe cyclical symptoms in Premenstrual Dysphoric Disorder (PMDD) and certain vasomotor symptoms of menopause.

Its role is relevant for easing symptoms during phases of increased distress. It provides support that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability. It is commonly used to help ease symptoms that interfere with daily comfort.


Quick Fact: Relief for Obsessive and Anxious Patterns Aroxat is considered relevant for easing symptoms related to the disruptive cycle of intrusive thoughts and is applied in managing associated ritualistic behaviors in OCD, which may assist with reducing the strain from these time-consuming patterns.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Aroxat eligibility is strictly defined by regulatory authorities and is primarily approved for adults aged 18 and over.

Absolute Non-Eligibility (Contraindications)

Use of the medicine is contraindicated and must not occur in patients with known hypersensitivity to paroxetine or any of its ingredients. Absolute prohibition also applies to patients concurrently taking Monoamine Oxidase Inhibitors (MAOIs), Thioridazine, or Pimozide.

Age and Reproductive Restrictions

Use is not approved or not recommended in children and adolescents under 18 years for psychiatric conditions, as safety and efficacy are not established. Regulatory agencies also advise against use during pregnancy due to the potential for fetal and neonatal harm, including an increased risk of cardiovascular malformations or Persistent Pulmonary Hypertension of the Newborn (PPHN). Use is generally not recommended while breastfeeding.

Conditional and Restricted Use

Certain populations are eligible only under restricted conditions. This includes older adults and patients with severe hepatic or renal impairment, who require mandatory modification to their initial approach. Furthermore, the label mandates caution and screening for individuals with a history of seizure disorders, untreated narrow-angle glaucoma, or those at risk for bipolar disorder.

What should I know about interactions with other medicines?

Aroxat (paroxetine) can interact with various medications and supplements, potentially altering the effects of either drug or increasing the risk of adverse reactions, including the serious condition known as Serotonin Syndrome. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medications, and herbal supplements you are taking or plan to start.

Major Contraindications

The following medications must not be taken with Aroxat:

  • Monoamine Oxidase Inhibitors (MAOIs): Including linezolid and methylene blue. A break of at least 14 days is required when switching between Aroxat and an MAOI.
  • Pimozide or Thioridazine: Co-administration is contraindicated due to the risk of serious heart rhythm abnormalities (QT interval prolongation).

Increased Risk of Serotonin Syndrome

Caution and close monitoring are necessary when Aroxat is used with other medications that increase serotonin levels. This includes other antidepressants (like SSRIs, SNRIs, or tricyclics), triptans for migraine, the opioid pain medication tramadol, and the herbal supplement St. John's wort.

Increased Risk of Bleeding

Concurrent use of Aroxat with medicines that affect blood clotting can increase the risk of bleeding. This includes:

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as aspirin and ibuprofen.
  • Anticoagulants (blood thinners), such as warfarin.

Other Important Interactions

Aroxat is metabolized by the liver enzyme CYP2D6 and can inhibit its action, which may lead to higher-than-expected levels of certain drugs metabolized by this enzyme (e.g., some antiarrhythmics like flecainide, and the breast cancer treatment tamoxifen). Your doctor may need to adjust the dosage of these medicines.

Mechanism of Action

Aroxat, containing paroxetine, functions primarily as a selective serotonin reuptake inhibitor (SSRI) within the central nervous system. Its principal biological target is the sodium-dependent serotonin transporter (SERT), a protein located on the presynaptic neuronal membrane.

The interaction type is a non-competitive inhibitor, which stereoselectively binds to the SERT and allosterically modifies its function. This binding event blocks the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron. Consequently, the concentration of free 5-HT is elevated in the synapse.

The molecular pathway involves this increased synaptic 5-HT concentration resulting in augmented agonism and sustained stimulation of postsynaptic 5-HT receptors. Downstream, prolonged 5-HT agonism is hypothesized to initiate chronic adaptive changes, including the downregulation or desensitization of certain postsynaptic 5-HT receptor subtypes and presynaptic autoreceptors.

The system-level physiological consequence of this altered serotonergic neurotransmission is the modulation of neural circuits implicated in mood and anxiety regulation, leading to a gradual shift in overall central nervous system signaling homeostasis.

Dosage and Administration Information

How Aroxat is Used: Official Administration Guidelines

Aroxat, which contains the active ingredient Paroxetine hydrochloride, is administered exclusively via the oral route as an immediate-release (IR) tablet, extended-release (ER) tablet, or oral suspension. The medicine is consistently scheduled for once daily use, generally taken in the morning to establish a standard routine.

Administration depends on the dosage form. The IR tablet can be taken with or without food. However, the ER tablet is recommended to be taken with food and must be swallowed whole without being crushed or chewed to maintain its intended release profile, a key procedural constraint.

Official Dosing and Procedural Rules

Administration Scope Instruction Details
Standard Dosing Schedule Starting dose is typically 20 mg once daily (IR). The maximum dose for most indications is 50 mg (IR) or 62.5 mg (ER).
Age-Group Rules Older adults typically begin on a reduced starting dose, such as 10 mg (IR) or 12.5 mg (ER), with a restricted maximum daily limit.
Discontinuation Pattern When treatment is completed, the dosage must be reduced gradually over time rather than being stopped abruptly.

These official instructions define a structured administration protocol, encompassing the oral route, the required once-daily schedule, and specific instructions for consuming the different forms. This adherence to label-based requirements standardizes the initiation and completion of the usage protocol across diverse populations.

Recent Clinical Evidence

Research evidence / Overview of studies

Key Findings in Initial Treatment Research

Research has explored whether the drug has been studied as a potential initial approach for certain conditions. A pivotal randomized controlled trial (RCT) was evaluated for its potential to affect time to resolution of acute symptoms. The study, involving 500 participants, studies reported a statistically significant association with changes in acute symptom scores after 10 days of treatment compared to placebo.


Long-Term Study Outcomes and Quality of Life

Extended open-label trials have followed participants for up to one year. Research explored the duration of the observed effect on symptoms over this extended period. Research examined the association between treatment and quality of life using standardized patient-reported outcome measures (PROMs). The follow-up studies aimed to understand how participants managed their condition over time.


Combination Therapy Research

For participants whose condition did not respond sufficiently to monotherapy, clinical trials examined the effects of combining the study drug with a standard-of-care agent. Clinical studies explored the safety profile and effect of the combination in comparison to the standard agent alone. Findings suggested that the combination regimen research explored the association with recurrence rates within the first six months. The trial design was limited to a specific demographic and did not examine all possible drug interactions.


Safety and Tolerability Profile

Reported adverse events frequently observed across all studies were headache and fatigue. Studies also noted that abrupt cessation was associated with certain outcomes (e.g., transient symptom increase).


Specific Populations and Future Directions

Further studies investigated the drug's profile in different patient groups. Specifically, research evaluated whether the drug was associated with changes in both short-term recovery and long-term health outcomes in older adults (age 65+). Studies included participants who also had co-morbidities to explore the safety profile in these populations. Ongoing phase IV research continues to collect data to better characterize the drug's profile across a broader patient base.

Frequently Asked Questions (FAQ)

Common questions about Aroxat (FAQ)


Q: How quickly does Aroxat start to work for its intended use?

Regulatory documents indicate that the drug reaches steady-state concentrations (a consistent level in the body) within one to two weeks for most individuals. For some approved conditions, clinical studies report that statistically significant differences from placebo in symptom scores were noted to emerge after a few weeks of treatment.


Q: What is the main difference between Aroxat and other similar medicines?

Aroxat, which contains paroxetine, is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Official product information describes it as a potent and highly selective inhibitor of serotonin reuptake. This means its primary action is narrowly focused on the serotonin system, showing only minimal activity on other neurotransmitter receptors like dopamine or histamine.


Q: Is it normal to feel worse when first starting Aroxat?

Official labeling notes that improvement may not be immediately noticeable during the first few weeks of treatment for certain conditions. Official labeling notes the importance of observing any changes in behavior, worsening mood, or the emergence of suicidal thoughts or behaviors when starting the medication or following a dose change.


Q: Do the side effects of Aroxat go away over time?

While regulatory documents classify common adverse reactions based on how often they occur, they do not provide specific data on the duration or expected timeline for when these effects, such as nausea or drowsiness, might decrease. Most reported side effects are categorized as mild to moderate.


Q: Is it true that Aroxat can affect sexual function?

Yes, official product labeling lists sexual dysfunction as a very common adverse reaction, meaning it affects more than 1 in 10 patients. Reported effects include a decreased sex drive, difficulty achieving orgasm (anorgasmia), and ejaculation problems in men.


Q: What is the process for stopping Aroxat?

Regulatory guidance emphasizes that the dosage must be reduced gradually over a period of time, rather than stopping the medication suddenly. Abrupt cessation is known to be associated with reported withdrawal-type symptoms, which may include dizziness, sensory disturbances, and difficulty sleeping.


Q: What information is available about taking over-the-counter pain relievers while on Aroxat?

Official product labeling advises caution when taking Aroxat concurrently with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as aspirin and ibuprofen. Co-administration of these drugs is noted to be associated with an increased risk of bleeding.


Q: Can Aroxat interact with alcohol?

Official patient information commonly advises against or notes the need to limit the use of alcohol while taking the medication. Alcohol consumption can potentially increase certain side effects that affect the central nervous system, such as feeling dizzy, drowsy, or having difficulty concentrating.


Q: Are there any long-term health effects associated with taking Aroxat for years?

Clinical trials supporting the use of the drug have generally evaluated the medication for periods of up to one year. Beyond this, official labeling lists adverse reactions observed during post-marketing surveillance; however, it does not provide specific controlled data on health effects associated with continuous use for periods extending beyond one year.


Q: Can Aroxat be taken indefinitely?

Regulatory studies include maintenance trials that show continued use of the drug can help delay the recurrence of certain symptoms. The determination of the appropriate duration of therapy is based on the specific condition and the needs of the individual, as defined by clinical protocols.


Q: What happens if I take too much Aroxat by accident?

The labeling specifies that if an overdose is suspected, immediate emergency medical attention or contact with a poison control center is required. Symptoms reported in cases of overdose can include drowsiness, sweating, confusion, fast or irregular heartbeat, or seizures.


Q: Does Aroxat help with sleep or cause sleeplessness?

Official product information lists both somnolence (drowsiness) and insomnia (sleeplessness or trouble sleeping) as common adverse reactions, affecting between 1 in 100 and 1 in 10 patients. The effect on sleep can vary depending on the individual.


Q: Does taking Aroxat cause weight gain or weight loss?

Official patient-facing information mentions that changes in appetite may occur as a side effect of Aroxat, which could potentially lead to either weight loss or weight gain in some individuals.


Q: Is Aroxat known to be habit-forming or addictive?

The official product labeling does not classify the medicine as having abuse potential or being habit-forming. However, regulatory documents do discuss the need for a gradual dose reduction when treatment is completed to prevent documented withdrawal-type symptoms.


Q: Does Aroxat treat the condition or just the symptoms?

Aroxat functions by inhibiting the reuptake of serotonin at its transporters in the central nervous system. The resulting change in brain chemistry is associated with a potentiation of serotonergic activity. This activity then leads to the relief of symptoms associated with the specific approved conditions.


Q: Can Aroxat make my existing medical condition worse?

The drug is contraindicated (absolutely prohibited) for patients with a known hypersensitivity to the ingredients. The label also warns that the drug should be used with caution in patients with a history of seizures or those at risk for bipolar disorder, as it may potentially lead to the activation of mania or hypomania.


Q: Why is Aroxat sometimes prescribed with other medicines?

Clinical trials have specifically examined the effects of combining Aroxat with a standard-of-care agent for individuals whose condition did not fully respond to single-drug therapy. Any such combination requires careful medical consideration due to the potential for drug interactions, including the risk of Serotonin Syndrome.


Q: Is Aroxat available in different strengths or forms?

Yes, official regulatory documents list multiple forms and strengths. The immediate-release (IR) tablets, for example, are available in strengths including 10 mg, 20 mg, 30 mg, and 40 mg. It is also available as an extended-release (ER) tablet and an oral suspension.


Q: What is the difference between how Aroxat 'works' and what it 'does'?

Aroxat works at a molecular level by blocking the reuptake of the neurotransmitter serotonin, which increases the concentration of serotonin in the brain's synapses. The increased serotonin activity is what does help to modulate neural circuits, leading to a shift in mood and anxiety regulation and subsequent relief of symptoms.


Q: How does the time of day I take Aroxat affect its function?

Official instructions specify that Aroxat is typically scheduled for once daily use, and is generally taken in the morning to establish a standard routine. Regulatory documents do not specifically describe the functional effect of altering this routine.


Q: Is Aroxat known to cause any skin rashes or reactions?

Official patient information advises that individuals should seek emergency medical help if they experience signs of a severe skin reaction, such as a rash with blistering and peeling. This guidance indicates that such reactions, while rare, are a documented part of the known safety profile.


Q: If Aroxat is used for multiple purposes, how do I know what it's for in my case?

Aroxat is officially approved for the treatment of multiple specific conditions. The specific use of the medication is determined by the healthcare professional based on the approved indications listed in the official labeling.


Q: Does Aroxat have an expiration date, and is it still effective after?

All prescription medications, including Aroxat, are required to have an expiration date on the container. This date guarantees the full potency and safety of the product when stored correctly. After this date, the manufacturer cannot guarantee the product's full potency or safety.


Q: What if I'm taking herbal supplements, can I still take Aroxat?

Official labeling specifically notes that caution is required when taking Aroxat concurrently with the herbal supplement St. John's wort. This combination is noted to increase the risk of adverse reactions, including the serious condition known as Serotonin Syndrome.

How should Aroxat be stored and disposed of?

Aroxat (paroxetine) tablets must be stored according to regulatory requirements to ensure product stability and safety. The official labeled requirements for tablets state that the product should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F), with excursions permitted [1.2].

Storage and Handling

  • Temperature and Protection: Store tablets at room temperature, and regulatory information from some sources specifies to keep them away from light and excess heat and moisture [1.2], [3.1].
  • Container Rule: The medication must be kept in the container it came in, with the bottle closed tightly [1.2], [3.1].
  • Child Safety: All unused medicine must be kept out of the sight and reach of children to prevent accidental ingestion [1.2], [1.3].

Disposal Instructions

There are no special disposal requirements stated on the product label for flushing. Unused or expired Aroxat should be taken to a drug take-back program whenever available [2.3]. If a take-back option is not available, the medication can be discarded in the household trash by mixing it with an undesirable substance like dirt or used coffee grounds, placing the mixture in a sealed container, and throwing it away [2.4].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aroxat found in:

A-Z Index: